Chemotherapy with or without trastuzumab

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Stage I breast cancer (pT1N0M0) generally has a favorable prognosis, often precluding adjuvant systemic therapy.
• However, biological heterogeneity exists within this subgroup, leading to varied outcomes.
• HER2 gene amplification/protein overexpression, though uncommon, is linked to increased recurrence risk in pT1N0M0 disease.

Purpose of the Study:

• To review available data on HER2-positive pT1N0M0 breast cancer.
• To explore the significance of intratumoural HER2 heterogeneity in this patient subset.
• To discuss the controversial role and challenges of anti-HER2 therapy in early-stage, node-negative breast cancer.

Main Methods:

• Literature review of studies on HER2 status in pT1N0M0 breast cancer.
• Analysis of subgroup data from adjuvant trastuzumab trials.
• Examination of diagnostic complexities related to HER2 heterogeneity and expression levels.

Main Results:

• Limited robust data exist for anti-HER2 therapy (trastuzumab) in HER2-positive pT1N0M0 patients.
• Subgroup analyses suggest proportional benefits of trastuzumab may be independent of tumor size and nodal status.
• Intratumoural HER2 heterogeneity complicates treatment decisions, as HER2 status exists on a continuum.

Conclusions:

• The role of adjuvant anti-HER2 therapy in HER2-positive pT1N0M0 breast cancer remains controversial.
• Current treatment protocols involve significant side effects (e.g., cardiotoxicity) and duration.
• Further research is needed to clarify the benefits and optimize the use of anti-HER2 therapy in early-stage breast cancer with HER2 positivity and heterogeneity.